Joshua Whitehill is an associate in the firm’s Litigation Department and a member of its Intellectual Property Group. Mr. Whitehill focuses his practice on patent matters, with a concentration in the areas of biotechnology and pharmaceuticals, including small molecules and biologics. Mr. Whitehill is an editor and contributor to the firm’s biosimilars blog, www.bigmoleculewatch.com, and the firm’s Guide to the Biosimilars Patent Dance. He joined Goodwin in 2010.

Experience

ERFAHRUNG

工作经历

Mr. Whitehill has participated in all phases of patent litigation, including pre-suit investigations, fact and expert discovery, numerous trials in various federal courts, and several appeals to the Federal Circuit. Mr. Whitehill has been involved in preparing petitions for inter partes review to the USPTO. Mr. Whitehill also counsels clients regarding litigation strategy and has experience in preparing patent opinions.

Representative matters include:

  • Pfizer Inc. et al. v. Teva Pharmaceuticals USA, Inc., No. 2:10-cv-00128-RBS-FBS (E.D. Va.). Representing Teva in patent litigation under the Hatch-Waxman Act against Pfizer concerning Teva’s generic version of VIAGRA® (sildenafil citrate).
  • Momenta Pharmaceuticals, Inc. et al. v. Teva Pharmaceuticals USA, Inc., No. 10-12079-NMG (D. Mass). Representing Teva in patent litigation against Momenta and Sandoz concerning Teva’s generic version of LOVENOX® (enoxaparin sodium).
  • ViiV Healthcare UK Ltd. et al. v. Teva Pharmaceuticals USA, Inc., No. 11-576-RGA (D. Del.). Representing Teva in patent litigation under the Hatch-Waxman Act against ViiV concerning Teva’s generic version of EPZICOM® (abacavir sulfate and lamivudine).
  • Janssen Products, L.P. et al. v. Lupin Limited et al., No. 10-5954-WHW (D.N.J.). Representing Teva in patent litigation under the Hatch-Waxman Act against Janssen, the University of Illinois, and the United States Government concerning Teva’s generic version of PREZISTA® (darunavir).
  • In re Bendamustine Consolidated Cases, No. 13-2046-GMS (D. Del.). Representing Cephalon in consolidated patent litigation under the Hatch-Waxman Act against numerous generic pharmaceutical companies seeking approval to market generic versions of TREANDA® (bendamustine hydrochloride).
  • Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc., No. 14-874-SLR-SRF (D. Del.). Representing Teva in patent litigation under the Hatch-Waxman Act against Merck concerning Teva’s generic version of NASONEX® (mometasone furoate monohydrate).
  • AstraZeneca Pharmaceuticals LP et al. v. Teva Pharmaceuticals USA, Inc., No. 14-1478-GMS (D. Del.). Representing Teva in patent litigation under the Hatch-Waxman Act against AstraZeneca concerning Teva’s generic version of BYETTA® (exenatide).
  • Valeant Pharmaceuticals International, Inc. et al. v. Mylan Pharmaceuticals Inc. et al., No. 15-8180-SRC-CLW (D.N.J.). Representing Actavis in patent litigation under the Hatch-Waxman Act against Valeant, Salix, Progenics and Wyeth concerning Actavis’s generic version of RELISTOR® (methylnaltrexone bromide).
  • Onyx Therapeutics, Inc. v. Cipla Limited et al., No. 16-988-LPS (D. Del.). Representing Fresenius Kabi in consolidated patent litigation under the Hatch-Waxman Act against Onyx concerning Fresenius Kabi’s generic version of KYPROLIS® (carfilzomib).
Professional Activities

Mr. Whitehill is a contributor to the firm’s biosimilars blog, www.bigmoleculewatch.com, and the firm’s Guide to the Biosimilars Patent Dance. He has been quoted in the press on matters relating to biosimilars and patent litigation. Mr. Whitehill is a member of the New York Intellectual Property Law Association (NYIPLA), including its publications and patent litigation committees.

Mr. Whitehill’s pro bono work includes representing a U.S. Army veteran in pursuing appeals related to his claims for disability benefits. As a member of the firm’s Neighborhood Business Initiative, Mr. Whitehill regularly organizes legal clinics at which teams of Goodwin attorneys provide pro bono legal services to entrepreneurs and small business owners in underserved neighborhoods.

Professional Experience

Prior to joining Goodwin, Mr. Whitehill worked as a paralegal and law clerk at Cooper & Dunham LLP, where he was involved in all aspects of U.S. patent prosecution and PCT international filings, particularly in the areas of pharmaceuticals, biotechnology and medical devices.

Recognition

While attending law school, Mr. Whitehill was a Notes and Comments Editor for the Brooklyn Journal of International Law.

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 2009
Brooklyn Law School

(cum laude)

B.A., Chemistry, 2004
New York University

Admissions

Bar

New York

Courts

U.S. District Court for the Southern District of New York
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Eastern District of New York
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师